Novo Nordisk’s Bold Gambit: Price Cuts and Restructuring Amid Market Pressure

Novo Nordisk DK0062498333

Facing intense competitive pressure, Danish pharmaceutical giant Novo Nordisk is implementing a radical strategic shift. The company has announced dramatic price reductions for its blockbuster drugs Wegovy and Ozempic, coupled with a significant corporate restructuring that will eliminate approximately 9,000 positions globally. This aggressive move comes as Novo Nordisk’s shares have plummeted more than 50% since the beginning of the year.

The market dynamics for GLP-1 medications have transformed considerably, with competitor Eli Lilly gaining substantial ground through its offerings Zepbound and Mounjaro. Market share data reveals the severity of Novo Nordisk’s position: the company’s international GLP-1 business share has collapsed from 71.6% to just 56.3% within a single year.